Semax and Selank are two short synthetic peptides developed in Russia, and they are cousins rather than twins. Semax comes from a fragment of adrenocorticotropic hormone and is studied mostly for attention, cognition, and neuroprotection. Selank comes from a fragment of the immune peptide tuftsin and is studied mostly for anxiety-related effects. Neither is FDA-approved in the United States. They overlap in some biochemistry but are not interchangeable, and most human evidence for both is small.
Where do these peptides come from?
The origin story explains most of the difference. Semax is a modified fragment of ACTH, the hormone that drives the stress response, and researchers stripped away the hormonal activity while keeping effects on the brain. Selank was built from tuftsin, a peptide tied to immune signaling, and reworked toward calming and anti-anxiety properties. Both were designed to resist rapid breakdown in the body, which is why they are given as nasal sprays rather than swallowed.
That shared design goal matters because it produced a shared quirk. A 2001 study in human serum found that both semax and selank inhibit enkephalin-degrading enzymes, the machinery that breaks down the body’s own opioid-like peptides. You can read that early enzyme work in the original report indexed at PubMed. It is one of the clearest points of biochemical overlap between the two.
Do they actually do different things in the brain?
This is where the interesting evidence sits. A 2020 functional connectomic study compared how the two peptides changed patterns of connectivity in the brain, and the finding was not that one is stronger than the other. It was that they shifted different networks. That work, available through PubMed, supports the idea that semax and selank are related tools with distinct fingerprints rather than two names for one effect.
Animal work points the same way. A 2017 study looked at both peptides in rats with 6-OHDA-induced parkinsonism, a model of dopamine-cell loss, and reported behavioral effects for each. The report is indexed at PubMed. It is a rodent model, so it says something about biology and very little about what either peptide does for a person with a diagnosed condition. That gap between mechanism and clinical proof is the honest center of this whole topic.
How do the two compare at a glance?
| Feature | Semax | Selank |
|---|---|---|
| Parent molecule | ACTH fragment | Tuftsin fragment |
| Most-studied direction | Cognition, attention, neuroprotection | Anxiety-related, calming effects |
| Shared biochemistry | Enkephalin-degrading enzyme inhibition | Enkephalin-degrading enzyme inhibition |
| Typical form | Nasal spray | Nasal spray |
| US regulatory status | Not FDA-approved | Not FDA-approved |
What is the regulatory reality in the United States?
Neither peptide is an approved drug here. Both were registered in Russia, but that registration carries no weight with the FDA, and there is no US label, no approved indication, and no large controlled trial base behind either one. Material sold in the United States is generally either compounded by a pharmacy or offered as a research chemical, and those are very different things. Compounded preparations are not FDA-approved products, and the agency’s own explainer on what compounding is and is not is worth reading at the FDA.
Research-chemical sellers add another problem: no clinical oversight, uncertain purity, and no accountability for what is in the vial. That is a meaningful safety distinction, not a formality.
Where does cost and access fit in?
Because there is no approved version, there is no insurance path and no manufacturer copay program for either peptide. Pricing is set by whichever supply route a person uses, and the range is wide. When a supervised source is involved, semax is usually offered through a compounding pharmacy with a clinician in the loop, and product pages such as formblends.com list the nasal-spray form that most studies used. A physician-supervised route costs more than an anonymous research vial and buys oversight the cheaper route does not include. Whether that trade makes sense is a decision for a prescriber who knows the person, not a checkout button.
How do these compare to other studied peptides?
It helps to place semax and selank against peptides with a deeper evidence trail, because the contrast is stark. Growth-hormone-releasing hormone and its analogs have been studied for decades. Foundational work on GHRH dates to the 1980s and is indexed at PubMed, and sermorelin, a GHRH analog, has a clinical literature covering adult growth hormone insufficiency and pediatric diagnosis in reviews from 2007 and 2008. GHRH-receptor antagonists have even been examined in cancer models, including gastric cancer signaling work from 2016. None of that transfers to semax or selank. It simply shows what a mature peptide evidence base looks like, and how far these two still are from it.
A 2025 review of therapeutic peptides in orthopaedics, indexed at PubMed, makes a similar point from another field: peptides are promising, and most of the interesting claims are still ahead of the confirming trials.
Key takeaways
- Semax leans toward cognition and neuroprotection; Selank leans toward anxiety-related effects. The split is a research tendency, not a rule.
- They share biochemistry, including enkephalin-enzyme inhibition, but imaging suggests different brain effects.
- Neither is FDA-approved, and most human data comes from small studies in one research tradition.
- A supervised compounded route costs more than a research-chemical vial but adds clinical oversight the cheaper route lacks.
Frequently asked questions
Are Semax and Selank the same kind of peptide?
No. Semax is derived from a fragment of adrenocorticotropic hormone, while Selank is based on a fragment of the immune peptide tuftsin. They are studied for overlapping but distinct effects and are not interchangeable.
Are either of these FDA-approved?
Neither Semax nor Selank is an FDA-approved drug in the United States. Both were developed and registered in Russia, and material sold here is generally compounded or supplied as a research chemical rather than an approved product.
Which one is studied for anxiety and which for focus?
In the published literature Selank is more often examined for anxiety-related and calming effects, while Semax is more often examined for cognition, attention, and neuroprotection. The distinction is a tendency in the research, not a firm clinical rule.
Do they work through the same mechanism?
They share some biochemistry, including effects on enkephalin-degrading enzymes, but imaging work suggests they act on different brain connectivity patterns. That overlap with divergence is a recurring theme across the studies.
Is one safer than the other?
The human safety record for both is limited to small studies, mostly from a single research tradition. Neither has the large controlled trial base behind approved medications, so safety comparisons between them are not well supported.
